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Abstract: Alzheimer’s disease is a lifelong progressive neurological disorder. It is associated with high
disease management and caregiver costs. Intelligent sensing systems have the capability to provide
context-aware adaptive feedback. These can assist Alzheimer’s patients with, continuous monitoring,
functional support and timely therapeutic interventions for whom these are of paramount importance.
This review aims to present a summary of such systems reported in the extant literature for the
management of Alzheimer’s disease. Four databases were searched, and 253 English language articles
were identified published between the years 2015 to 2020. Through a series of filtering mechanisms,
20 articles were found suitable to be included in this review. This study gives an overview of the
depth and breadth of the efficacy as well as the limitations of these intelligent systems proposed for
Alzheimer’s. Results indicate two broad categories of intelligent technologies, distributed systems
and self-contained devices. Distributed systems base their outcomes mostly on long-term monitoring
activity patterns of individuals whereas handheld devices give quick assessments through touch,
vision and voice. The review concludes by discussing the potential of these intelligent technologies
for clinical practice while highlighting future considerations for improvements in the design of these
solutions for Alzheimer’s disease.
Keywords: Alzheimer’s disease; intelligent sensors; smart sensors; smart devices; robots; smart
homes; remote health monitoring; activity monitoring; user-centred design
1. Introduction
Globally, neurological diseases (ND) are the primary cause of disability-adjusted life
years (DALYs) [1]. Of these, stroke and Alzheimer’s along with other types of dementia
are the two leading causes of DALYs [2]. Moreover, neurological diseases are the second
leading cause of death all over the world [1]. People suffering from neurodegeneration
undergo neuronal structure and functional losses. These abnormal structural changes in
the brain provide a hindrance to normal brain function. As in the case of Alzheimer’s, the
typical neuropathological hallmarks are the accumulation of beta-amyloid plaques and
the formation of protein tau-tangles beside others [3]. These lesions provide interruptions
in the synaptic transmissions from one neuron to another. The neurons start to lose their
connections with the other neurons in the brain [4]. This results in the deterioration
of the normal brain and human body functions [5]. Thus, the people that suffer from
neurodegenerative diseases such as Alzheimer’s slowly start to lose their cognitive abilities
and motor functions. This eventually renders them to be dependent on others for carrying
out their activities of daily life (ADLs). To date, no standard cure has been put into practice
for these conditions, although there have been extensive attempts in this regard [6].
Besides genetics and inheritance, age is one of the greatest risk factors for Alzheimer’s
disease (AD). According to the 2020 annual report by the Alzheimer’s Association, 3% of
people between the age of 65 and 74 years are currently suffering from Alzheimer’s disease.
This number drastically increases with the increasing age window. This is evident from the
statistics that show 17% of the people aged from 75 to 84 years, and 32% of the total people
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aged 85 and above are currently suffering from Alzheimer’s disease [7]. Neurodegeneration
is relatively a slow process. However, once started, it cannot be reverted.
At present, the diagnosis of Alzheimer’s disease heavily depends on neuroimaging
techniques. These tests include brain scans such as Magnetic Resonance Imaging (MRI),
Positron Emission Tomography (PET) and Computed Tomography (CT). These scans
although being effective, prove to be a challenge for people with neurological conditions.
These methods are bulky, expensive and even invasive as in the case of PET scan. Dedicated
lab requirements result in random episodic monitoring of the Alzheimer’s patient. This
increases the chance for late detection of further neuronal damage. Moreover, the majority
of the existing therapeutic solutions for Alzheimer’s include physical exercises to retain the
physical functionality of the body and cognitive exercises for strengthening the existing
brain cells. However, for these type of solutions, dedicated time and frequent or continuous
help of either a clinician, nurse, formal or informal caregiver are required. This all amounts
to the social, emotional, economical and physical burden on the caregivers. Given the
progressive nature of the disease, the individuals suffering from it must be monitored
regularly or continuously.
With the advancements in ubiquitous and pervasive computing, cloud and wireless
technology, topping it all up with Artificial Intelligence (AI), the literature is rich with their
application in dementia [8–10]. The proliferation of miniature sensors in smart devices
such as smartphones and tablets, and ambient sensors that are designed for smart homes
are playing a substantial part in the remote and continuous monitoring of Alzheimer’s
disease [11]. Sensors form the backbone of these intelligent systems which enable these
to sense various signals of interest from the environment. These sensors monitor signals
from the humans and as well as the surroundings thus providing contextual information.
These signals are then monitored and processed by embedded processors which provide
an automatic response through actuators. This feature of the provision of apt feedback
and response distinguishes these smart and intelligent technologies from the conventional
ones [12–14]. This particular strength can be used for the management of diseases where
continuous monitoring and adaptive responses are required, such as in Alzheimer’s disease.
These technologies have the potential to provide autonomous care along with continuous
yet remote monitoring of the patient improving their quality of life [15].
A handful of review studies exist that focus on the complex and specific needs of
Alzheimer patients using assistive technology. Costanzo et al. [16] talk about the treatment
and diagnostics of Alzheimer’s disease and mild cognitive impairment (MCI) with the
help of telemedicine. They emphasize the fact that the use of technological services such as
emails and video conferencing can prove effective sources for the detection and follow-up
between the patient and the doctors. The work in [17] presents a scoping review of the
general technological solutions for AD patients. Pillai and Bonner-Jackson [18] provide
an overview in their study on the randomized clinical trials for AD patients using general
information and communication systems. The systems mentioned in their study are used
for monitoring cognitive and functional decline. The study outlines the strengths and
weaknesses of these systems focusing on randomized clinical trials; however, it includes
published articles until 1 September 2014. Hence, it is not an up-to-date overview of these
solutions anymore. Elfaki and Alotaibi [19] present an overview of only the mobile health
applications used for the assistance of AD. Studies [20,21] deal with the role of Virtual
Reality Technology used for the diagnostics and cognition training of Alzheimer patients.
Based on the existing reviews, the following research gaps are identified:
• The existing reviews focus on the role of telemedicine or the general information
and communication technologies for Alzheimer’s disease [16,17]. No recent review
exists that focuses on the management of Alzheimer’s disease alone, using intelligent
systems and devices.
• The existing review studies focus on a sub-class of intelligent or smart assistive
technologies such as mobile phones or virtual reality for AD [19–21] and do not cover
a broader spectrum of intelligent feedback systems.
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• Some of the review studies are general in nature, covering intelligent technological
solutions for all types of dementia, including Parkinson’s disease, etc., such as in [14].
This hampers the understanding of how these intelligent solutions can effectively be
used for the complex and intricate needs of Alzheimer’s patients.
• The existing reviews either focus on part of the disease progression such as the early
detection of AD [9,20,22] or therapy [21] or only on the monitoring of the functional
decline of AD patients [18]. No review study exists that categorizes the intelligent
solutions for the complete progression of Alzheimer’s disease, hence, providing
a comprehensive picture of the role of these sensing technologies for Alzheimer’s
disease.
Thus, there is a need for a recent up to date review that highlights the existing
intelligent and smart technologies that are capable of assisting and managing Alzheimer’s
disease. This review study aims to provide an up-to-date state of the knowledge for
the intelligent assistive technological solutions for Alzheimer’s disease by searching the
literature in the last five years. Moreover, according to [14], the number of intelligent
assistive technologies is doubling every five years. Hence, the current systematic review
intends to address the above-mentioned research gaps and contributes to the literature in
the following ways:
• It provides a detailed overview of the recently researched intelligent technologies
mentioned in the literature, focusing only on Alzheimer’s disease. Thus, the findings
of the review will help in translating the researched solution into clinical practice
as well as remote diagnosis and monitoring of the disease. The review tends to
raise awareness of the potential of these automated intelligent solutions among the
stakeholders (clinicians, caregivers and Alzheimer’s patients). Moreover, emphasizing
only on Alzheimer’s disease will facilitate future research focus on the complex needs
and particular symptoms of Alzheimer’s patients.
• The review covers a broad spectrum of intelligent solutions designed and researched
for the complete progression (diagnosis, monitoring and therapy) of Alzheimer’s dis-
ease. This will aid in provision of a broader picture and a comprehensive understand-
ing of the role of these sensing technologies throughout the Alzheimer’s progression.
• The review study also aims to evaluate the efficacy and usability of these proposed
solutions. For this purpose, the review focuses on the studies, identified in the searched
databases, which implemented the solution and involved Alzheimer patients for the
validity of their proposed intelligent solution.
• The review study discusses the practical implications of these intelligent solutions.
Moreover, it also highlights the limitations of the current researched studies and the
areas that need consideration for better and improved solutions, thus indicating new
directions for researchers in this field.
The remaining review article is organized as follows: Section 2 describes the materials
and research methodology undertaken for the systematic review. It states the research
questions for the current study, followed by the detailed description of the database
search and the articles’ screening methodology. Section 3 gives a comprehensive analysis
of the results identified in the literature search. This is followed by Section 4, which
discusses the results, the social and economic impact of these technologies and how they
can play a vital role in improving the quality of life of Alzheimer patients and of those
who are responsible for caring for and treating them. This section also highlights the
current limitations identified in the searched studies and provides suggestions for future
improvements. Finally, Section 5 provides the conclusion of the review study.
2. Materials and Research Methodology
To provide an oriented and impactful outcome, the research questions addressed
in our review article are explicitly stated in Table 1. The first two questions highlight
the overall motivation behind the study. They focus on the kind of intelligent sensing
technologies that exist in the literature for the care of Alzheimer’s disease and the purpose
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served by these technologies, in its management. Keeping in view the scope of the current
article, we tend to focus on intelligent sensing technologies that can provide low-cost
solutions and do not require dedicated labs or expensive equipment for the diagnosis,
treatment and monitoring of Alzheimer’s disease patients. The third research question is a
focused research question (FRQ). It tends to focus on how the different stakeholders are
involved in the design of these systems and devices and what are the challenges faced and
limitations in the existing solutions. Emphasis is given on how the proposed designs or
prototypes have used the user-centric design approach.
Table 1. Research questions.
Type Research Question
RQ1
What intelligent technological solutions exist in the literature that may help
in the assistance and management (diagnosis, monitoring and therapy) of
Alzheimer’s disease?
RQ2
How do the proposed intelligent technological solutions help in the
assistance and management (diagnosis, monitoring and therapy) of
Alzheimer’s disease?
FRQ How are these intelligent systems and devices incorporating the user-centricdesign and what are the limitations in the existing designs implementations?
RQ: Research Question; FRQ: Focused Research Question.
Systematic Search Methodology
A systematic search was carried out using the PRISMA guidelines [23]. Four databases
were explored. The database search engines accessed were: Scopus, PubMed (Medline),
Web of Science and IEEE Xplore. The articles searched were from 2015 until the 6 January
2021, the date on which the databases were searched. Only English language articles
indexed in the above search engines were considered for inclusion in this review. The
document type selected for the current review included only ‘Articles’ that were published
in the journals whereas all remaining document type categories, such as books, book
chapters, conference proceedings, etc., were excluded.
Significant consideration was given while choosing the keywords for searching the
required studies. Various combinations were tried. As an example, the very first combi-
nation that was used by the authors was “Alzheimer” AND “smart OR intelligent” AND
“sensor OR device”. After seeing the results, a modification was made by adding the
keywords ‘assist, assistive or robot’ with ‘device OR sensor’, to widen the spectrum of
the required results. Hence, the final combination of the keywords used was the com-
bination of: (Alzheimer) AND (smart OR intelligent) AND (device OR sensor OR assist
OR assistive OR robot). These keywords were searched in the data fields of the ‘Article
title, Abstract and keywords’ in the advanced search option. For example, the search
strategy in the IEEE Xplore database performed on the 6 January, 2021 was: (“All Meta-
data”: Alzheimer) AND (“All Metadata”: smart OR “All Metadata”: intelligent) AND
(“All Metadata”: device OR “All Metadata”: sensor OR “All Metadata”: assist OR “All
Metadata”: assistive OR “All Metadata”: robot). The same was repeated for Scopus, Web
of Science and PubMed databases.
This search methodology resulted in a total of 253 journal articles (Scopus: 63, Web of
Science: 60, PubMed: 23 and IEEE Xplore: 107). Next, 57 duplicates were removed, first by
using the EndNote software and then by screening the articles for the title, abstract and
author names. Based on the scope and inclusion criteria, 121 articles were removed after
screening the title and abstracts. Finally, reading of the full text of the remaining articles
was carried out by the first author and thorough discussions between both the authors led
to the inclusion of 20 articles. The inclusion and exclusion criteria used by the authors is
described in detail below.
To be included in the current review study the articles needed to
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• Have included an intelligent or smart solution for the diagnosis, monitoring, assistance
or therapy of Alzheimer’s disease.
• Include Alzheimer’s or MCI patients along with sufficient information about the
methodology of the design and study. However, those studies were also included
whose participants were older adults aged 55 years and above. The studies including
young healthy controls were also included if they were used as a control group, acting
as comparators to the AD patients.
• Have sufficient information about the evaluation metric and result validation.
• Be written in the English language.
• Be a published journal article.
• Be published between the years 2015 to 2020.
However, the articles were not included if
• They had AI algorithms implemented on neuroimaging scans, EEG signals or similar
data from existing Electronic Medical Records.
• Used specialized or dedicated lab equipment for the detection of metal ions, chemical
structures or drug delivery inside the body.
• Were theoretical such as interviews or perspectives from caregivers.
• Implemented activity recognition or systems to mimic human behaviour for smart
future agents.
Figure 1, below, describes the PRISMA flow diagram for the searching, screening,
eligibility and inclusion of the identified articles for the current review.
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3. Results
Following the research methodology detailed in Section 2, a total of 20 articles were
included in the analysis and classification for the current review paper. Two broad catego-
rizations of the intelligent technologies used in the article studies were observed. These
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include self-contained handheld devices and the distributed systems. Out of the studies
selected, 11 fell under the category of distributed systems. These distributed systems
included the installation of various sensors in a residential setting or a care home. These
sensing nodes collected various signals from the patients and environment, sending them
to the cloud or other processing units. After computations, suitable actuators in the homes
were activated providing intelligent feedback to Alzheimer’s patients. The remaining nine
studies dealt with the implementation of solutions involving technologies such as smart
devices, the development of software applications that run on these smart devices, and
virtual assistants such as robots.
The following subsections describe in detail the kind of sensing technologies and their
supporting systems used in the proposed solutions. This addresses Research Question 1
which states that ‘What intelligent technological solutions exist in the literature that may
help in the assistance and management (diagnosis, monitoring and therapy) of Alzheimer’s
disease?’ The different study outcomes, that is, the various stages of disease profiling
(diagnosis, monitoring and therapy), require different methodology and require the moni-
toring of different signals. Hence, the initial part of the results provides a description of the
methodology, participants involved and the intervention used, describing the effectiveness
and acceptability of the proposed solutions. This addresses Research Question 2 which
states that ‘How do the proposed intelligent technological solutions help in the assistance
and management (diagnosis, monitoring and therapy) of Alzheimer’s disease?’
To evaluate the effectiveness of the researched intelligent solutions, the comparator
used in the study for result validation is also clearly reported. Some studies compared their
results to a standard clinical test while others used a control group to explain their evidence-
based outcomes. These descriptions then are followed by tables that further classify the
studies implementing the distributed and self-contained solutions for Alzheimer’s disease.
The tables summarize the duration, participants, technology used, study design and the
particular measurements monitored by the sensors and devices for the study outcomes
(diagnosis, monitoring and therapy). The tables also highlight the key findings, limitations
and report whether the design or study included the user-centred design approach or not.
These thus address the last Focused Research Question which states that ‘How are these
intelligent systems and devices incorporating the user-centric design and what are the
limitations in the existing designs implementations?’ The limitations and challenges are
also further discussed in detail in Section 4 of the review article.
3.1. Distributed Systems
Distributed systems are systems that have multiple sensing nodes, data processing sub-
systems and actuators that are activated according to the requirement and context as sensed
by the sensors. These multiple components interact with each other through computer
networks via network protocols. According to [6], the subsystems “host processes and use
a set of protocols to aid in the coherent execution of the distributed activities”. The studies
that realized these distributed systems were conducted longitudinally in either the care
homes, nursing homes, labs or residential homes where the Alzheimer’s patients resided.
The following subsections provide a classification of the studies based on their outcomes.
3.1.1. Diagnosis of Alzheimer’s Disease
In the clinic, there are standard tests used for the diagnosis of Alzheimer’s disease.
Besides the neuroimaging scans which indicate structural changes in the brain, there
are other questionnaire-based tests as well. These tests evaluate the cognition of an in-
dividual through questionnaires or similar screening tools. Common examples include
Clinical Dementia Rating (CDR) [24], Mini-Mental State Exam (MMSE) [25] and Montreal
Cognitive Assessment (MoCA) [26]. However, these tests provide a sporadic and sub-
jective assessment. The continuous monitoring of the vulnerable population can result
in an early diagnosis as well as objective measurement for the detection of Alzheimer’s
disease progression.
Sensors 2021, 21, 4249 7 of 27
Autonomous detection of early-stage Alzheimer’s, MCI, was carried out in a study
by Akl et al. in 2015 [27]. The study included 97 participants all aged 70 years or above
with CDR score < 0.5 and MMSE > 24 at the start of the study. Each participant was
living independently in a home equipped with smart sensors. They were continuously
monitored for a period of 3 years. CDR and MMSE assessment was repeated by the end of
each year, for the three years. For comparison, at the start of the study, participants were
categorized as cognitively intact or baseline MCI. The data collected was that of walking
speed and activity throughout the day. Passive infrared sensors, installed in the homes,
were used to collect the walking speed data. Signal processing and machine learning
algorithms (Support Vector Machine (SVM) and Random Forest (RF)) were applied to the
data. The authors concluded that the most important measurements in detecting MCI were
weekly trajectories, the variation coefficient of walking speed, coefficient of variation of the
subject’s morning and evening walking speed along with their age and gender. In their
study, they successfully distinguished MCI individuals from the cognitively healthy elderly.
In another study by Akl et al. in 2017 [28], the authors used the data from smart
homes of 68 elderly patients having the same characteristics and in the same environment
as mentioned in their earlier study [27]. However, in [28], they built generalized linear
models (GLMs) of the everyday activities of the individuals and did not use any predefined
measures for the detection of cognition. They concluded that by using normalized Kullback-
Leibler divergence on the GLMs with 12-week window size, their technique resulted in a
successful generalized solution for the detection of MCI. They also noticed that while the
participants transitioned to the MCI stage there was no significant slowing in the gait speed.
A detection system based on Alzheimer disease ontology using agent-based tech-
nology, smart IoT devices including mobile phones and RFIDs was implemented by
Kaur et al. [29]. Data collected from 374 patients with ages 60 to 96 years was used in the
study. A cloud platform for the storage of the data and their processing was used. The
detailed information of the patients including all the demographic, health (including symp-
toms) and MMSE data was fed to the smart system for the detection of Alzheimer’s disease.
The study was qualitatively validated based on accuracy, usability, readability and conve-
nience as compared to the similar four existing ontologies in the literature. Quantitatively,
it was verified by using 100 patients out of the 374 for testing. Various classifiers were used
such as Naïve Bayesian, J48 and the ontology Bayesian Network, with the latter performing
the best. The measure used for assessing the accuracy of the system was the area under the
curve (AUC) [30] with a value of 0.76. This was the greatest as compared to other classifiers
used in the study. In addition to this Bayesian Network decision model, the system also
monitored the physical location of the 100 patients using RFIDs that continuously updated
the clinician through an android application developed for the purpose. The application
also gave reminders to the patients for medicine and had memory recall exercises. Thus,
assisting the patients as well as diagnosis.
In the study done by Alberdi et al. [31], the authors attempt to predict various symp-
toms that are an indication of Alzheimer’s disease. Smart-home sensor data were used to
detect decline of cognition, changes in mobility and mood decline. The duration of the
study was more than 2 years, and a total of 29 older adults were involved in the study. Vari-
ous standard tests for mobility, cognition and mood were carried out at the beginning of the
study and repeated after a period of every six months. For mobility, the tests included Arm
Curl [32], Timed Up and Go Test (TUG) [33]. For cognitive decline, the standard test used
was Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) [34]
and Prospective and Retrospective Memory Slips (PMRQ) while the mood was assessed
using Geriatric Depression Scale (GDS) [35]. Based on the tests scores, the 29 participants
aged 73–97 years old were classified as cognitively healthy (N = 13), at-risk (N = 10) and
participants with cognitive difficulties (N = 6). Regression analysis was performed, and the
study concluded that mobility, depression and cognition can reliably be predicted using
smart home sensors. The results also indicated that mobility scores were correlated most
with behaviour followed by cognition. The daily routine and socializing patterns of the
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participants were important indicators for the various symptoms’ detection. Moreover,
the overnight activities such as visits to the toilet and sleep patterns and mobility routines
were correlated with cognition. Finally, in-home and outing activity was considered to be
related to a diagnosis of depression although it lacked statistical evidence.
3.1.2. Continuous Monitoring of Alzheimer’s Patients
Alzheimer patients suffer a range of functional deterioration along with a decline in
cognition. The continuous context-aware monitoring can help in timely detection of this
descent in daily capabilities providing opportunities for timely interventions. The sensors
used in the distributed systems can measure certain signals that may reveal information
about the individual’s changing health and personal behaviour. Algorithms and models
then can make a viable assessment to predict the declining functionality of the individual.
The continuous monitoring of the individuals also enables them to assist either automati-
cally using intelligent voice assistants, pre-recorded messages or can alert the caregiver
for a timely intervention. The studies included in the review provide with assistance as
described below:
(a) Detection of Abnormal Behaviour
Abnormal behaviour is one of the main challenges when it comes to Alzheimer’s
patients. Alzheimer patients often suffer from agitation and decline in mood. Alvarez
et al. [36] used a range of sensors including wearable bracelet, zenith camera, Microsoft
Kinect v2, magnetic binary sensors and wireless sensor network beacons to detect abnormal
behaviour. These were used in an indoor multi-patient setting. The signals measured from
the sensors included physiological data such as heart rate and skin temperature along
with motion and location tracking data. The study included 18 patients in a hospital
setting, aged 55–94 years, however, not suffering from cognitive issues. These patients
were classified as very ill, moderate ill and mildly ill by their doctors. The duration of
the study was 10 weeks. A weighted probabilistic model was used depending on the
fusion scheme of the collected data from the multiple sensors used. The system was able
to detect abnormal behaviour with an accuracy of 98.4%. This decision was based on
the correlation calculation of the activities performed by the individuals and where those
particular activities were performed.
(b) Detection of Autonomy in Activity Performance
Automatic and objective detection of autonomy in the everyday tasks of Alzheimer
patients was carried out by Karakostas et al. [37]. In total 109 participants were part of
the lab-based study across two different geographical regions (France and Greece). From
France, there was a total of 11 participants which included both, MCI patients and Healthy
Controls (HC). Similarly, the remaining 98 participants were categorized as 27 AD, 38 MCI
and 33 Healthy Controls (HC). These were assessed on MMSE scores (both sites), Functional
Rating Scale for Dementia (FRSSD) and Functional Cognitive Assessment. The labs were
instrumented with the necessary information computed technologies; video cameras, tags
on house objects and mobile phones to run applications were used. The data collected from
these sensors were used for the automatic detection of the (i) participants and (ii) tasks
performed, and (iii) autonomy level was done using AI and signal processing algorithms
on video signals. The instrumental Activities of Daily Living (iADLs) used for assessment
were making an online payment, preparing a drink, medicine box preparation and talking
on the phone. Results indicated a statistical correlation between the findings from both
geographical regions. Moreover, using statistical analysis using the ANOVA (analysis of
variance) test, the results confirmed that the autonomy level of HC is much better than
MCI patients, and similarly, the autonomy level of MCI patients is better than that of AD
patients.
(c) Provision of Assistance
Barley et al. [38] used a smart auto-prompting system to assist people with cognitive
problems. The system developed was used for guiding the patients with cognitive problems
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or memory problems while they perform their iADLs. The eight activities performed
included common household chores such as cleaning the kitchen, using the telephone,
doing laundry, and cooking. The participants in the study included 15 elderly aged
59–91 years old. All of them met the criteria for mental disorders defined by the Diagnostic
and Statistical Manual of Mental Disorders-IV-TR. A university furnished apartment fitted
with smart sensors, actuators, speakers, cameras and TV screens was used as a testbed. The
prompting system consisted of pre-recorded automated messages. If the user could not
follow the instructions given by the auto-prompt system, they were told to go to the nearest
TV screen. There a video with all the required steps for the particular task was shown on
how to complete the activity they were having difficulty performing. Two experimenters
observed the reactions of the elderly patients to how they responded to the automatic
prompting systems. Qualitative assessment was carried out with a team of 4 experts from
gerontology, nursing neuropsychology and assistive technology. It was concluded that
context and the level of cognition level affects the acceptability of auto-prompting systems,
as the people suffering from cognition problems showed levels of stress while responding
to non-human prompts.
Similarly, in a study by Cavallo et al. [39], a system using smart domiciliary sensors
was developed to assist Alzheimer patients and their caregivers. The design phase of the
system involved a team of physicians, patients, caregivers and psychologists. Initially,
they tried to assess specific user needs through interviews, hence, giving a good example
of user-centric design. Based on the results, they identified four key concerns, including
functional monitoring, alerting of an emergency, social behaviour and support for cognition.
Based on these results, they designed solutions for the four domains mentioned. A total
of 14 Alzheimer disease patients were recruited for the study, aged 80 years and above.
According to MMSE, they were classified as AD-phase 1 and 2 patients. To address the
concerns the researchers developed an in-home bed-chair monitoring system, patient
location indicator and a home enter exit system. The sensors used for the bed-chair system
were two metallic plates that acted as a closed switch when someone sat on them. The
door open-close was monitored by a magnetic switch while to indicate the location the
patients had to wear a device integrated with Global Positioning System (GPS) and Global
System for Mobile Communication (GSM). All the sensors communicate with a remote
computer monitored either by a caregiver or spouse of the patient through Zigbee. To
support cognition, the system included the use of music and videos related to the past
of the users for therapy purposes acting as stimuli. The duration of the study was not
fixed, and only those systems were implemented in the home of the patients as per need
or specified by the users themselves. The authors concluded that the acceptability and
usefulness value of the implemented systems was 50% and 30%, respectively, as reported
by the users after the study. Another important conclusion was that the wearable device
was not suitable for AD patients with adverse symptoms.
Night-time wanderings are another common characteristic of Alzheimer’s patients.
Radziszewski et al. [40] devised a system that tries to detect a night-time wandering of
patients and tries to return them to their bed. The study included a single participant, a
female aged 78 years old. According to her score on the MoCA test, she was an MCI patient.
The system consists of 30 ambient smart-home sensors that were installed in her home
where she lived alone. Moreover, a smart wristband was used as a wearable and smart
home objects such as LED bulbs and lamps were also installed in the home. The first week
of the study was used to test the sensors and understand the participant’s routine. The
next two weeks were used for the testing phase of the study. In this phase, only the data
were collected, but no assistance was provided. However, the caregiver was also involved
at this stage for collaboration. K-means algorithm and clustering techniques were used to
classify the patients’ day and night activities. Then actuators, speakers for voice messages
and calming music apparatus were installed in the home for assistance, and after testing
the system for a week, a 15-day validation study period was carried out. At the end of
this, MoCA and Dementia Rating Scale (DRS) were performed again. The results indicated
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that the data collected in the 42-day study were insufficient for determining nocturnal
patterns; however, the small clustering of activities gave an overall view to the caregiver
for better assistance.
The system developed by Kaur et al. [29] also assists by generating automatic alarms
and message reminders to help Alzheimer patients in memory. It also has cognitive support
exercises, and through a GPS, it can guide an AD patient back to a rehabilitation centre.
(d) Monitoring Functional and Cognitive decline
In an 8-year longitudinal study carried out by Lyon and co-authors. [41], smart sensors
were strategically placed in 480 homes of an elderly population. All the participants were
70 years or older in age and had scores MMSE > 24 and CDR ≤ 0.5 at the beginning of
the study. The sensors include passive and wrist-worn sensors such as actigraph acting as
ground truth. The sensors were used to monitor the gait, activities performed, mobility
patterns, leisure time (computer usage and socializing) and medicine adherence of the
residents of the homes. Statistical analysis, logistic regression along other predictive
analysis were applied to the multi-domain data. Results showed that using multimodal
data collected from sensors, they could identify decline in cognition, loneliness and mood
anomaly within a short period. These were identified using the changes in mobility,
socializing and activity patterns as observed by the sensors. Some of the symptoms of
decline and Alzheimer disease progression were detected within six months. It is also
noted that various behaviours such as speed of computer usage and sleep patterns are
different for MCI patients as compared to people in the later stage of Alzheimer’s.
3.1.3. Therapy and Rehabilitation
The effective use of assistive technology on the cognition, behaviour and functional
challenges experienced by Alzheimer patients was evaluated by Lazarou et al. [42]. In their
study, they recruited 18 patients (12 MCI, 6 AD patients) and divided them into 3 control
groups. Each group had 4 MCI patients and 2 AD. The MCI patients were selected on
Peterson criteria [43], and the AD participants were selected according to the Diagnostic
and Statistical Manual of Mental Disorders (DSM-V) criteria [44]. The duration of the
study ranged from 4 to 12 months. The interventions used were off-the-shelf IoT devices
including wireless tags for in-home objects, Infrared (IR) motion sensors, sleep monitoring
sensors, wearable band and ambient depth cameras. Sleep, motion and activity patterns
were monitored for the first and second control group. Based on the information generated
by these sensors, the first group received automatic, clinical updates, recommendations and
alerts for their care and other non-pharmacological purposes. The second group received
these automated prompts based on self-reported methods. The third group did not have
the system installed in their homes neither did they receive any proposed interventions.
All the participants underwent MMSE and various neuropsychological tests before and
after the study. The study concluded that the group that was continuously monitored and
received all the appropriate automatic, system-generated interventions, and hence, the
timely treatment showed significant improvement in cognition by the end of the study. The
cognitive and memory abilities of the patients in group 1 remained better intact, even better,
as compared to group 2, which was receiving partial on-demand interventions. Moreover,
the results of group 2 were better than that of the third group that received no treatment
and no automatic monitoring system. Hence, the functional and cognitive decline of the
third group progressed as expected in Alzheimer’s disease.
Table 2 provides a summary of all the studies implementing the distributed systems
for the diagnosis, assistance and therapy of Alzheimer’s disease.
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3.2. Handheld Devices
This section deals with the intelligent sensing technologies that are not spread through-
out the care homes, nursing homes or individual’s smart home. These instead are based on
interactive devices such as a smartphone or a tablet which takes the user input through
touch, video or voice. Robotic interfaces, socially assistive robots and virtual assistants are
also part of this category of intelligent sensing technologies. Mobile phones and tablets
have software applications running on them that provide adaptive feedback to the user
using the touch screens. Out of the 20 studies, 9 were categorized as those whose so-
lutions involved self-contained devices. These devices were further classified into the
following groups: smartphones/tablets, interactive robots, applications implemented on
smartphones/tablets and smart furniture.
These devices are being used for the diagnosis, therapy and assistance of Alzheimer’s
disease. These sensing technologies are playing their part in the diagnosis and detection
of various Alzheimer related symptoms such as cognitive and memory decline, tremors
and visio-motor coordination skills. For therapy purposes, there exist devices that are
working to aid for medicine adherence of the Alzheimer’s patient. Moreover, devices
and applications are implemented for cognition and memory exercises. Music therapy for
mood-boosting purposes and for strengthening episodic memory is also being carried out.
The following subsections provide a classification of the studies based on their outcomes.
3.2.1. Diagnosis of Alzheimer’s Disease
Gonzalez et al. [45] designed a system that evaluates the memory of an individual.
Their system includes a three-door cupboard installed with magnetic switch sensors for
each door of the cupboard, a Raspberry Pi and an external battery. The 23 participants
involved in the study include adults in the range of 18–60 years old. The young adults were
included as a control group for comparison purposes. The attributes assessed in the study
were memory and the reaction time of an individual. To validate the memory assessment,
a shorter version of the standard test ‘face-name pairs’ [46] along with a self-reported
memory test [47] were used as an evaluation and validation metric. The algorithm on
the Raspberry Pi recorded information of the number of attempts of finding an object
in the cupboard versus actually finding the object. An experimenter also independently
observed the individuals during the task. The memory measurements from the study
were compared with that of the standard tests. Pearson correlation test was performed.
A high correlation between the results from the designed system and the memory tests
were observed. Moreover, the study results indicate that no correlation exists between the
reaction time of older adults versus younger adults.
The study carried out by Suzumura et al. [48] also tends to diagnose the decline in
cognitive function using finger dexterity. They were able to do so using a smart terminal
device ‘JustTouch’ which was used to assess the various finger tapping patterns. These tests
included rhythmic (left or right hand and then both simultaneously) and sounded rhythmic
(using either hand) patterns. The response time was also calculated with precision. The
participants in the study consisted of 31 AD patients (mean age 74.2 years) and 15 people
diagnosed with MCI (mean age 74.3 years). Healthy controls (HC) (mean age 74.6 years)
also participated in the study. MMSE test was carried out for all participants at the start
of the study. The statistical analysis using Spearman’s correlation coefficient shows that
significant differences exist between the three groups (AD, MCI and HC) in the contact
duration, rhythm and response time (lag time). A negative correlation was also indicated
between the MMSE and contact duration of the touch screen.
Lee et al. [49] built a small play apparatus consisting of four different colours Light
Emitting Diodes (LEDs), an Arduino board and a small speaker. This system is connected to a
smartphone using Bluetooth. The system is capable of diagnosing cognition problems as well
as providing treatment for them. The diagnosis is carried out by calculating the reaction rate as
a response to the game. The cognition therapy is carried out by providing repeated cognition
stimulations and taking care of the hand, vision and hearing coordination. The participants
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included in the study were healthy control adults in their 20 s and 70 s, and 10 measurements
from each patient were taken while the other group consisted of 14 people suffering from
cognition problems and MCI patients, and they were tested twice as much as those of the
first group. It was noticed that the response rate for cognition of the elderly in their 70 s was
300 ms slower than that of those in their 20 s. However, the response time of the patients
with cognitive issues was 9.64 s slower as compared to healthy controls in their 20 s while
5.53 times slower than those in their 70 s. Hence, the device was successful in differentiating
the age-related as well as detecting impairment in cognition of the individuals.
Low-cost haptic feedback robotic interface was developed by Bartoli et al. [50]. The
apparatus consists of a computer screen on which a visual target appears and a haptic
interface. The apparatus was developed to detect the Visio-motor deficits of Alzheimer
patients. The commercially available haptic device, Omni SensAble, was integrated with
the Windows XP monitor using customized software. The device helps to draw the hand
trajectory while the user tries to follow the visual target on the screen. The study consisted
of controlled randomized trials. The control group involved 20 healthy, cognitively sound
adults aged between 53–90 years, while the experimental group consisted of 20 AD patients
aged 57–82 years of age. The reaction times, position tracking of the object and stability of the
position tracking were observed for trials that lasted less than an hour. In addition, MMSE
and standard vision tests such as Rey’s Figure copy-REY-Clock Drawing test were performed.
Results of the study indicate that there was a marked correlation between cognitive abilities
and memory to that of visio-motor performance. The experimental group was significantly
slower in response time. Moreover, the Attentive Matrices test and MMSE were negatively
correlated with reaction time. The tracking error also increased for the AD patients, and hence,
the performance of position tracking was better with the cognitively well group.
3.2.2. Assistance in Everyday Activities
Fardoun et al. [51] built a prototype system consisting of a smartwatch and mobile that
helps Alzheimer patients in recognizing people. They made use of a smartwatch that had a
built-in camera and cloud technology. The Alzheimer patient takes the picture of the person
in front of him/her using the smartwatch. The picture is then sent to the mobile which is
then compared to a pre-existing customized database on the cloud data. A face recognition
algorithm recognizes the face and displays the information of the person on the screen of
the smartwatch. This aids the Alzheimer’s patient to recognize the person, thus helping in
memory rehabilitation. The prototype was tested on 41 people aged 55 to 72 years old that
experienced no visual difficulties. Results show that although the system works well in
face recognition, the vision of the information displayed on the small smartwatch screen
proved to be challenging for the elderly especially those with Alzheimer’s.
Rudzicz et al. [52] made use of a human interactive robot named ED that could have a
conversation and direct patients with cognition problems in their daily tasks. They assessed
the feasibility of using such a robot in a nursing home-like setting, interacting with 10 AD
patients simultaneously. The robot assisted the AD patients with verbal prompts after
visually monitoring. The robot was movable and had a video display screen, speakers and
cameras installed on it. Speech recognition was an integral part of the robot used in the
study. A total of 10 AD patients along with their caregivers were recruited for the study.
Throughout the study, the robot was teleoperated, and when a caregiver was required or
intervened, the robot was no longer used for assistance in that particular task or time. It was
used while guiding the patients to perform simple tasks that had a specific number of steps
involved such as making tea. It also guided them or followed them to the washroom. It was
noted that the patients seldom interacted with the robot in two way-conversations. It was
better used when engaging in familiar tasks; however, human-human (patient-caregiver)
interactions were more used by the patients in interview type conversations. The AD
patients ignored the robot prompts over 40% of the behaviours that indicated confusion.
However, the automatic speech recognition capability of the robot was assessed to be 70%
which was greater than the already existing in the literature.
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McGoldrick et al. [53] evaluated an application ‘MindMate’ that was developed to
help and support people with later stages of Alzheimer’s (dementia). It was developed
to assist in memory tasks by using reminders. The study was carried out to assess the
usability of the application to aid in memory management. Three participants diagnosed
with Alzheimer’s (at MCI stage) according to ICD-10 criteria (International Statistical
Classification of Diseases and Related Health Problems) and reported to experience memory
problems were recruited for the study. Moreover, partners (responsible for taking care of the
patients) also participated in the study. Baseline performance was recorded by the carers
of the patients for the first phase without using the application for five to seven weeks.
Then, a weekly assessment was made for 5 weeks after the intervention was introduced.
One of the AD patients withdrew from the study in the first week of the intervention.
The patient was irritated with the reminders and the difficulty of turning them off. In
addition to observational data analysis, Tau-U (Unified Theory of Acceptance and Use
of Technology) [54] was also carried out. Results showed significant improvement in the
memory performance for the two remaining patients.
3.2.3. Therapy and Rehabilitation
Lyu et al. [55] developed a system consisting of a smart robotic dog along with
an adaptive fuzzy logic inference module and cloud technology. A corresponding web
application along with a few sensors such as pulse oximeter, electroencephalogram (EEG)
and smartwatch was also part of the system. The overall system was used to detect
symptoms of pneumonia in AD patients. The robotic dog was used to detect the emotions
of the AD patient and respond to them accordingly. When simulated, it played music.
For AD patients, music therapy is used to calm their mood and sometimes it is used for
their memory rehabilitation. Furthermore, depending on the beat of the music, it can also
encourage movements in AD patients [56]. The smart dog provided the patients with
companionship as well as it was designed to lessen the caregiver burden. The system was
tested on 18 AD patients diagnosed with middle to late-stage AD and their caregivers aged
25 to 78 years old. Before the usage of the system, various questions regarding time and
stress burden were asked from the caregivers through the Caregiver Burden Inventory
(CBI) system. The system was tested for 12 weeks day and night. After the test period, the
caregivers were again asked questions in the form of a user satisfaction questionnaire and
CBI. Results showed that the robotic dog was a great help in managing behaviour, sadness
and agitations of the AD patients. This resulted in lessening the physical, emotional, time
and social burden of the caregivers to a significant extent. The system also helped in
reducing the frequency of night-time wanderings and agitated mood of AD patients. The
system was rated in terms of usability (89%), readability (74%), convenience (78%) and
accuracy (63%), according to the survey.
Stoekle and Freund [57] also developed a smart personalized music device for the
therapy of AD patients. The prototype was developed using open-source code of Java
script and Hypertext Markup Language (HTML) on an Apple iPad 4. It consisted of a
simple user interface with few textual features and more visual features. The 40 songs
in the music player consisted of classical (10 songs), North American folk (5 songs) and
25 popular songs. The cross-sectional study took place in a care setting for memory loss
and the disabled population. The study included the presence of the researcher, caregiver
and the 5 selected sample of elderly patients, aged 62–69 years. The patients although
not diagnosed with AD were considered a close proxy with AD patients. The data were
collected through videos and direct observation. Results from the observational study
show that the device can independently be used by the patients, and they enjoyed listening
to the songs, and their mood was alleviated. The device was also able to automatically
detect user preferences of songs.
Table 3 below provides a summary of all the studies implementing the self-contained
device solutions for the diagnosis, assistance and therapy of Alzheimer’s disease.
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4. Discussion
With the ever-increasing population of the elderly, the number of Alzheimer patients
is also likely to increase. According to a 2019 report, ‘Projections of older people with
dementia care in the United Kingdom, 2019–2040′, Wittenberg et al. state that currently
7.2% of people in the United Kingdom (UK) are suffering from dementia. This number
is expected to increase exponentially in the years to come. Moreover, the increase in the
prevalence rate of dementia is estimated to be 80% by the year 2040 [58]. This indicates a
substantial increase within the next two decades, while in the United States of America
(USA), it is estimated that the current number of people that are suffering from Alzheimer’s
over the age of 65 years is 5.5 million [59]. According to the ‘Centre for Disease Control
and Prevention, the problem of Alzheimer’s disease and related dementia is to double
by the year 2060 in the USA [60]. These numbers tend to increase in other parts of the
world as well. As the average life expectancy increases all over the globe, the prevalence of
Alzheimer’s disease patients will tend to increase too. Global statistics state that in 2018,
the total number of people with dementia was 50 million. This number is projected to rise
to 152 million, which is a 204% percentage increase by the year 2050 [61].
The high incidence numbers of this vulnerable population are associated with a high
cost of care. The complex physiological changes, functional assistance and neuropsychiatric
needs of Alzheimer’s patients pose social and financial pressures on society, families and
the overall healthcare systems. According to the research study of 2013, by Hurd et al. [62],
Alzheimer’s and related dementia is the costliest disease in western countries. They state
that out of all the types of dementia, the most expensive is Alzheimer’s disease. Almost
160 billion dollars were spent annually on these diseases [14,63,64]. According to the
Alzheimer’s statistics report, these costs in 2018 have risen to 277 billion dollars [64]. These
costs will keep on increasing with the ever-growing disease’s prevalence, as stated above.
Such high costs indicate that automated, sustainable and low-cost technological solutions
need to be put into practice. The intelligent solutions as identified by the review can
help individuals with their everyday tasks yet provide remote up-to-date health status
information to the clinicians and caregivers for timely interventions whenever required.
The main objective of this review paper was to see the advancements in recent liter-
ature and the proposed solutions that exist for the management of Alzheimer’s disease.
These have the potential to assist the clinicians and Alzheimer’s patients, in the selection
of appropriate solutions mapping them into their daily practice for Alzheimer’s disease
management. The advantage of implementing such systems and devices in the daily life of
Alzheimer patients is manifold. Moreover, the current study aimed to identify research
gaps and challenges faced to orient the researchers for a better user-centric design for the
intended purpose. The research studies reviewed and presented in the results section in
this article have been classified according to the sensing technology (Research question 1).
The details of how these technologies are playing their role in the care and management of
Alzheimer’s disease have also been discussed in the results section (Research question 2).
The discussion section presents an overview of these results presented in Section 3 and the
associated challenges and limitations, in accordance with the focused research question of
this review paper.
The breadth and depth of the reviewed research articles in the current study indicate
prospective outcomes of these intelligent sensing technologies for viable solutions for
Alzheimer’s disease. The range of solutions and the type of assistance they provide
indicates that these intelligent sensing technologies, for the use of intricate diseases such as
Alzheimer’s, are still a developing area. However, the widespread use of smart devices
and miniature sensing technologies is paving the way for them to be integrated into daily
living without being noticed by the users. Moreover, their ability to provide context-
aware adaptive responses increases their prospects in being suitable for use in managing
Alzheimer’s disease.
These solutions include both the distributed systems as well as the handheld devices
and the robots. The distributed systems increase the possibilities of remote health monitor-
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ing of AD patients. These systems are suitable for in-home and care-home settings. The
idea of intelligent assistive technology is to provide automated context-aware updates that
can not only help in the early diagnosis but also monitor the progression of the disease.
Moreover, it enables timely therapeutic interventions based on the progression speed of
the disease. This helps in less damage as compared to no monitoring or even self-paced
decision making as is evident by the study by Lazarou et al. [42].
4.1. Practical Implications of Using Intelligent Systems and Devices
The following subsection discusses the strengths of these systems with a focus on the
sensors used, signals being monitored through the sensors, and how these can play a role
in the early diagnosis, daily monitoring and therapy of Alzheimer’s disease patients in the
comfort of their homes as well as in care home settings.
4.1.1. Diagnosis of Alzheimer’s Disease
It is observed that in the case of the distributed systems, the diagnosis of Alzheimer’s
disease is being done by monitoring the activities and mobility patterns of the subjects of
interest. The signals monitored in the studies include walking speed [27,28], changes in
mobility, absence from home, visitors, sleep patterns and toilet visits at night-time [31].
Gait speed was measured using passive infrared sensors installed in the homes of the
patients. While absence from home, the presence of visitors and night-time toilet visits were
monitored by magnetic door binary switches. In [29,31], RFID tags on active IoT devices
carried by the patients such as mobile phones were also used to track the location and
motion sensors were used to assess the environment of the user. Making using of Machine
Learning algorithms, Bayesian inference and regression models, the studies use these sensor
data to correlate these signals with the prevalence of cognitive decline and depression. A
decline in cognition and mood changes both are symptoms of Alzheimer’s disease.
In the case of handheld devices, the most common signal monitored is the pattern of
finger tapping and measuring response time, reaction time and rhythm [45,48,49]. These
have been monitored by smartphones and simple home furniture which was made intelli-
gent using magnetic switches and programming an Arduino board. The smart cupboard as-
sessed the decline in memory which is also a common symptom of early-stage Alzheimer’s.
Whereas, smart devices such as mobile phones and tablets are equipped with built-in
motion and magnetic sensors. According to the study results, the response and reaction
time are relatively much slower for those who suffer cognitive problems as compared to
healthy controls. Mobile applications that access these sensors and calculate the response
time can be of use and easily put into practice in daily lives especially in care-home setting
and personal homes. The major advantage of such devices is that the results are quick, and
their ubiquitous nature nowadays makes it a lucrative prospect for the early detection of
Alzheimer’s disease. Moreover, simple low-cost systems, as described in [45,50], that assess
memory and visio-motor coordination of individuals can easily be implemented not only
aiding in a quick diagnosis, but also these kinds of systems can help in therapy purposes
as well. The repetition of such tasks strengthens their motor and cognitive abilities thus
aiding in slowing down the progression of the neuronal and functional damage caused by
Alzheimer’s disease.
4.1.2. Monitoring and Assistance of Alzheimer’s Disease Patients
The smart-home sensors, such as magnetic switches attached to doors and cupboards,
pressure mats for monitoring the presence of a person in and out of the bed or chair and
tags attached to the everyday household objects can give valuable activity and contex-
tual information. This data collected by various ambient home sensors combined with
some wearables that monitor the physiological parameters such as heart rate and temper-
ature can be used to assess the erratic mood changes of Alzheimer’s patients [36]. The
monitoring of the mobility and daily activities of the patients can help in assessing the
autonomy, abnormal behaviours and functional decline [37,39,41] of Alzheimer’s patients.
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The monitoring of daily activities can also aid in assisting caregivers, alerting them during
abnormal activities or risky situations such as falls and night-time wanderings [40]. The
provision of assistance in daily tasks, such as cleaning, cooking etc., such as that in [38]
through automated recorded messages can enhance the confidence of the elderly patients,
ensuring autonomy and self-reliance. Moreover, the system introduced in [40] that assists
the patient back to bed through the activation of actuators can help reduce the caregiver
burden, allowing the caregiver and family members also take adequate rest.
In the case of self-contained devices, the assistance is provided by sending reminder
alerts for tasks and medicine [53] or using robots that are equipped with various sensors
such as cameras, temperature sensors, distance sensors, motion sensors, sensing the envi-
ronment and using Natural Language Processing to interact with the patients [52]. There
are commercial robots present for the aid of Alzheimer’s patients; one such example is
PARO (a seal robot). The robot assesses the mood of the patient and provides her company
by responding to the gestures of the patients [65]. These socially assistive robots prove to
be successful mood boosters for Alzheimer’s patients.
4.1.3. Therapy of Alzheimer’s Patients
The system described in [42], makes use of ambient smart home sensors, such as
motion sensors and tags attached to simple everyday household objects as well as wearables
to monitor the sleep and mobility patterns of the subjects. The tags were also attached to
drug boxes to monitor the subject’s adherence to medicine. The study results indicated that
the group which received automated reminders for medicine and regular updates from
the clinicians based on their daily activities showed marked improvement in cognition
as compared to the groups receiving the self-assessed, on-demand intervention and no
intervention at all. This study indicates that continuous monitoring at home and sharing of
the sensor data with clinicians can result in timely interventions and avoid drastic neuronal
damage. Hence, such systems can practically play a vital role in slowing the progression of
Alzheimer’s disease.
In the case of handheld smart devices, [55] introduced a robotic dog that could monitor
mood changes, temperature and heart rate using various sensors. The results of the study
indicate that the mood of the patients improves due to the interactive robot, posing less
burden on the caregivers. Similar results were evident from a simple music application [57],
intended to boost the mood of Alzheimer’s patients.
4.2. Future Research Directions for Intelligent Systems
The literature indicates the potential of intelligent systems; however, the translation
of these systems to clinical practice is hampered by a few limitations. Below are listed a
few shortcomings and suggestions for future research to make intelligent systems more
effective for the diagnosis, monitoring and therapy for Alzheimer’s disease.
(a) Maintaining long-term Patient Databases for Distributed Systems
A positive aspect of the distributed systems is that they can continuously or regularly
share updates with the clinician. However, to make such solutions effective, database
management systems are required as an integral part of the system. These systems should
maintain the patient’s history to easily identify any irregular changes in the times to come.
The studies that focused on the diagnosis of cognitive decline either have used datasets
from the patient databases or have resulted as part of larger projects such as the dem@care
and Oregon Center for Aging and Technology (ORCATECH) [27,28]. Moreover, Alberdi
et al. [31] have studied 29 patients over a period of 2 years while the study in [41] resulted
from the patient data of 480 homes collected over a period of 8 years. Hence, these studies
indicate that the diagnosis and indication of cognitive decline is a slow process that requires
time, and it may vary from patient to patient.
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(b) Multi-person settings in Distributed System Designs
Most of the studies just mentioned for database management and implementing
distributed systems have taken place in societies that had smart homes built for individual
patients. Although this may be a lucrative solution for people living independently, it is
not suitable for homes where more than one person resides. Such examples include the
family of the patient living with her or multi-person settings such as care homes. As for
those homes with more than one person, the first challenge comes from recognizing the
person (person identification). As the simple motion sensors used in most of the studies can
only detect motions and not identify by whom the motion was made. Hence, the motion
sensors placed in common areas may detect motion through anyone present, thus making
the activity profiling of the individual challenging unless indoor tracking is also done.
(c) Maintaining Privacy of the Individuals
The prospect of continuous monitoring of Alzheimer patients by using simple smart
home sensors that are commercially and readily available in the market seems much ad-
vantageous. These sensors are being used for the continuous monitoring of the individuals,
recognizing the daily activity patterns and then separating these from the changing or
risky profiles such as less socializing, less movement and increased visits to the toilets.
Moreover, these systems can monitor behavioural changes which is also an important
neuropsychiatric symptom of Alzheimer’s disease. This symptom cannot be judged or
indicated in short clinical visits. However, these distributed systems use cameras such as
in [36–38] along with other sensors for the intended purpose. The drawback of the usage
of cameras is the infringement of privacy.
The solutions need to be designed such that the privacy and citizenship of the patients
are guarded. Although cameras can provide a more direct context-aware sensing system
these also cause severe privacy infringements. Privacy is not only an issue in the sensing
technology; in the case of data storage systems, there is also a potential threat of misuse of
the patient data. Huge data storage systems and well maintained electronic medical records,
on one hand, are lucrative aspects for the researchers but, on the other, are vulnerable to
privacy risks. Hence, there is a need for clear policies for maintaining the data privacy
rights of these storage systems. Policymakers and concerned organizations should come
together to look into this issue.
(d) Need of Increase in Systems for Detection of Anomaly in Behaviour
A study in [66] was conducted by Gary and Mary West Health Institute in collaboration
with the Centre to Advance Palliative Care (CAPC) to understand the most challenging
behaviours of Alzheimer’ patients. They surveyed over 500 caregivers by forming four
in-person focus groups. According to their study, the most challenging behaviours of
Alzheimer’s patients is agitation, aggression and changing moods of the patients. This
problem amounted to the maximum, contributing 25% among other challenges. This
challenge of abnormal behaviour was followed by other problems such as speech decline
or repeated speech (12%), wanderings of the patients (10%), inconsistence (10%), late-
day confusion (8%), sleeplessness and adherence to medicine (6% and 4%, respectively).
Given these statistics of the problems, only behavioural issues account for one-fourth of
the remaining problems. Hence, feasible and practical solutions to mitigate this issue
should be researched. According to the reviewed studies, only a couple of the studies are
detecting mood issues [36,55] while only one study focuses on emotional encouragement
through music [57]. Hence, further research should be carried out giving more attention to
incorporate behavioural changes of Alzheimer’s patients.
(e) Improving Provision of Everyday Assistance
Intelligent sensing technologies are also being used to assist Alzheimer patients by
helping them in their everyday tasks. This assistance is being provided by first observing
the patients in a context that is, understanding the surroundings of the patient and then
guiding them through alerts and messages. Alzheimer’s disease patients have difficulty
Sensors 2021, 21, 4249 23 of 27
performing their daily tasks especially in adhering to medicine due to forgetfulness along
with dressing difficulties because of disorientation and confusion. Moreover, a very typ-
ical symptom and challenge experienced by caregivers is the night-time wanderings of
Alzheimer’s patients. Studies have developed systems to aid these problems through
soothing music, automated voice messages and video assistants [37,39,40,52]. However,
these solutions also have a few limitations.
(i) Privacy Concern: The first is that some of the studies are using cameras which raise
the privacy concerns of the stakeholders.
(ii) Minimum User-Centric Approach: It has been observed in the studies themselves, that
AD patients feel stressed while responding to automated voice commands. Moreover,
in [39], although the system alerts the caregivers of the risky behaviour of the AD
patient, the acceptability and usability rate were 50% and 30% which is quite low. The
application used in [53] as a reminder of medicine also deals with only 3 AD patients
of which one left the study due to agitation experienced by the reminders generated
by the application.
(iii) Low Accuracy: The study that assisted the AD patient back to bed during night-time
wandering involves only one patient, and the duration of the study was not enough
to reach viable conclusions. Hence, a limited number of AD patients in the studies
and low accuracy rates are of concern. Moreover, Fardoun et al. [51] developed the
device to aid in-person recognition for the AD patient; however, the screen size of the
watch made it difficult for them to read or see the information. Hence, efforts should
be made to take these considerations into account to improve the design solutions
for assistance.
(f) Increase in Therapeutic Solutions
As observed in the reviewed literature, the distributed systems and devices are also
being implemented for non-pharmacological therapeutic purposes. The handheld devices
either use a simple apparatus, mobile applications or virtual assistants that guide the
patients in various ways through their therapies. Studies such as [50,53] aid the patient
through automatic exercises for visio-motor coordination therapy, cognitive exercises or
alerts aiding in memory. The smart robotic dog and the music player [55,57] also provide
emotional support through music therapy. However, in the case of distributed systems [42],
the only therapy that is being provided is medication alerts and timely interventions by
the clinician or caregiver. This limitation indicates an inadequate number of solutions for
the therapy of Alzheimer’s patients.
(g) Robust Diagnostic using Handheld Devices
In the case of handheld devices, the studies [48,49] try to assess the cognition decline
through finger tapings using a mobile screen and a simple play apparatus attached to
the mobile. The diagnosis of other symptoms of functional decline related to the disease
progression has been done only using self-contained devices. These diagnostic symptoms
include the decline of memory [45], and visio-motor coordination [50]. These methods are
quick, and the results confirm their accuracy. Although these devices have their strengths
in a quick decision, a limitation mentioned by [50] is that the user can learn the patterns
of visio-motor games if played again and again. This limitation can be addressed if the
cognitive exercises are designed based on randomized patterns. This will make the exercise
a little challenging yet useful.
(h) Involvement of Clinicians in Solution Designs
Another important observation that was seen is that clinicians were minimally in-
volved in the development and design of the solutions for Alzheimer’s disease. Most
of the studies involve caregivers as stakeholders for their perspectives while designing
the distributed systems, applications and handheld devices. Progression is a slow pro-
cess, and to truly translate the technological solutions into long-term healthcare practice,
the clinicians also need to be involved in the design and development phase of these
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technological solutions. Such a limitation implies that the proposed solutions cannot be
confidently implemented by caregivers or clinicians for the management of Alzheimer’s
disease. However, this constraint also indicates the challenge faced by the researchers
proposing solutions for such an intricate disease. The direct involvement of the vulnerable
population requires great care and precautions for many reasons. The prime reasons being
the old age, easily agitated moods and frailty of such individuals. Furthermore, the widely
varying symptoms between various individuals and the range of age of the patients also
pose further challenges for user-centred designs. Hence, there is a need for the combined
efforts where the researchers, clinicians, formal and informal caregivers can collaborate to
come up with solutions that are effective and safe resulting in the user-centric design in
true spirit.
5. Conclusions
The current study presents an overview of the intelligent technologies designed and
developed for Alzheimer’s disease management, mentioned in the recent literature from
2015 to 2020. Alzheimer’s is an incurable, progressive neurodegenerative disease, which
with time results in serious dysfunction of the individual suffering from it. Intelligent
sensing technologies have the potential to provide low cost, sustainable clinical and home-
based solutions as compared to the existing expensive and dedicated lab-oriented solutions.
These can help in prolonging the stay of the patients at home and reducing hospitalizations.
The continuous monitoring of the patients and regular updates being sent to the clinicians
can result in timely therapeutic interventions. This can potentially aid in reducing the
extensive healthcare costs spent every year on the management and care of Alzheimer’s
disease. Moreover, with the existing challenge of the pandemic, these intelligent solutions
become all the more necessary. Now that Alzheimer’s patients are forced to stay at
home for their safety, interventions of smart technology can provide a viable solution.
These technologies can help in avoiding visits to clinics and hospitals for regular check-
ups and follow-ups, minimizing the risk of exposing the vulnerable elderly to other
disease risks such as COVID-19. Automated solutions integrated into the daily lives of
Alzheimer’s disease patients cannot only help in assisting the individuals but also reduce
the stress and burden of the formal and informal caregivers. These solutions if effectively
implemented can help improve the quality of life of the patients and their caregivers.
Hence, awareness is to be increased among the societies and people who are directly
involved in the care of Alzheimer’s patients. They need to be made aware that how these
intelligent, context-aware, ubiquitous and low-cost technological solutions can help in
prolonging the life of their loved one by making it easy, safe and independent. However,
the practical implementation of these intelligent technological solutions is hampered by
a few limitations and challenges as discussed in the discussion section above. Hence,
this review article not only highlights the practical role of intelligent sensing technologies
for Alzheimer’s patients but also suggests future improvements for further research in
this area.
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